Advanced search
1 file | 236.44 KB

Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture

(2015) CURRENT PHARMACEUTICAL DESIGN. 21(28). p.4000-4006
Author
Organization
Abstract
Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established drug therapy for AAA. Since the probability of death from a ruptured AAA still remains high, preventive elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best treatment option. However, perioperative complications are problematic as elective AAA repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, significant efforts have been made to identify pharmacological tools that would slow down AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical intervention. In this review, we discuss recent findings addressing molecular targets that could potentially treat AAA, particularly addressing: statins, classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, interleukin-1 beta inhibition, anti-angiogenic agents and urocortins.
Keywords
Abdominal aortic aneurysm, VENTRICULAR HYPERTROPHY, statins, renin angiotensin system, tetracyclines, interleukin-1 beta, MATRIX METALLOPROTEINASES, MEDIAL NEOVASCULARIZATION, HYPERCHOLESTEROLEMIC MICE, ANG-II, II-INFUSED MICE, SMOOTH-MUSCLE-CELLS, ENZYME-RELATED CARBOXYPEPTIDASE, RENIN-ANGIOTENSIN SYSTEM, E-DEFICIENT MICE

Downloads

  • Fraga-Silva - CPD.R1 final.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 236.44 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Fraga-Silva, Rodrigo, Bram Trachet, and Nikolaos Stergiopulos. 2015. “Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture.” Current Pharmaceutical Design 21 (28): 4000–4006.
APA
Fraga-Silva, R., Trachet, B., & Stergiopulos, N. (2015). Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture. CURRENT PHARMACEUTICAL DESIGN, 21(28), 4000–4006.
Vancouver
1.
Fraga-Silva R, Trachet B, Stergiopulos N. Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture. CURRENT PHARMACEUTICAL DESIGN. Bentham; 2015;21(28):4000–6.
MLA
Fraga-Silva, Rodrigo, Bram Trachet, and Nikolaos Stergiopulos. “Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture.” CURRENT PHARMACEUTICAL DESIGN 21.28 (2015): 4000–4006. Print.
@article{6922129,
  abstract     = {Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established drug therapy for AAA. Since the probability of death from a ruptured AAA still remains high, preventive elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best treatment option. However, perioperative complications are problematic as elective AAA repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, significant efforts have been made to identify pharmacological tools that would slow down AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical intervention. In this review, we discuss recent findings addressing molecular targets that could potentially treat AAA, particularly addressing: statins, classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, interleukin-1 beta inhibition, anti-angiogenic agents and urocortins.},
  author       = {Fraga-Silva, Rodrigo and Trachet, Bram and Stergiopulos, Nikolaos},
  issn         = {1381-6128},
  journal      = {CURRENT PHARMACEUTICAL DESIGN},
  keyword      = {Abdominal aortic aneurysm,VENTRICULAR HYPERTROPHY,statins,renin angiotensin system,tetracyclines,interleukin-1 beta,MATRIX METALLOPROTEINASES,MEDIAL NEOVASCULARIZATION,HYPERCHOLESTEROLEMIC MICE,ANG-II,II-INFUSED MICE,SMOOTH-MUSCLE-CELLS,ENZYME-RELATED CARBOXYPEPTIDASE,RENIN-ANGIOTENSIN SYSTEM,E-DEFICIENT MICE},
  language     = {eng},
  number       = {28},
  pages        = {4000--4006},
  publisher    = {Bentham},
  title        = {Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture},
  url          = {http://www.ncbi.nlm.nih.gov/pubmed/26306835},
  volume       = {21},
  year         = {2015},
}

Web of Science
Times cited: